Cardio-renal syndrome type 5: epidemiology, pathophysiology, and treatment
- PMID: 22365162
- DOI: 10.1016/j.semnephrol.2011.11.007
Cardio-renal syndrome type 5: epidemiology, pathophysiology, and treatment
Abstract
The cardio-renal syndromes (CRS) recently were defined systematically as disorders of the heart or kidney whereby dysfunction of one organ leads to dysfunction of another. Five types of CRS are defined. The first four types describe acute or chronic cardio-renal or renocardiac syndromes. Type 5 CRS refers to secondary cardio-renal syndrome or cardio-renal involvement in systemic conditions. It is a clinical and pathophysiological entity to describe the concomitant presence of renal and cardiovascular dysfunction. Type 5 CRS can be acute or chronic and it does not strictly satisfy the definition of CRS. However, it encompasses many conditions in which combined heart and kidney dysfunction is observed. Because this entity has been described only recently there is limited information about the epidemiology, clinical course, and treatment of this condition.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment.Semin Nephrol. 2012 Jan;32(1):31-9. doi: 10.1016/j.semnephrol.2011.11.005. Semin Nephrol. 2012. PMID: 22365160 Review.
-
Cardiorenal syndrome in critical care: the acute cardiorenal and renocardiac syndromes.Adv Chronic Kidney Dis. 2013 Jan;20(1):56-66. doi: 10.1053/j.ackd.2012.10.005. Adv Chronic Kidney Dis. 2013. PMID: 23265597 Review.
-
Cardiorenal syndrome type 5: clinical presentation, pathophysiology and management strategies from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).Contrib Nephrol. 2013;182:174-94. doi: 10.1159/000349970. Epub 2013 May 13. Contrib Nephrol. 2013. PMID: 23689662
-
Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatment.Semin Nephrol. 2012 Jan;32(1):26-30. doi: 10.1016/j.semnephrol.2011.11.004. Semin Nephrol. 2012. PMID: 22365159 Review.
-
[Cardio-renal syndrome: the challenge in heart failure treatment].Acta Med Port. 2011 Mar-Apr;24(2):285-92. Epub 2011 May 20. Acta Med Port. 2011. PMID: 22011601 Review. Portuguese.
Cited by
-
Forced diuresis oriented by point-of-care ultrasound in cardiorenal syndrome type 5 due to light chain myeloma-The role of hepatic venogram: A case report.Clin Case Rep. 2021 Mar 16;9(4):2453-2459. doi: 10.1002/ccr3.4069. eCollection 2021 Apr. Clin Case Rep. 2021. PMID: 33936712 Free PMC article.
-
The Need to Identify Novel Markers for Early Renal Injury in Cardiorenal Syndrome.Cells. 2024 Jul 30;13(15):1283. doi: 10.3390/cells13151283. Cells. 2024. PMID: 39120314 Free PMC article. Review.
-
miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome.Front Pharmacol. 2020 May 15;11:726. doi: 10.3389/fphar.2020.00726. eCollection 2020. Front Pharmacol. 2020. PMID: 32499708 Free PMC article. Review.
-
Cellular apoptosis in the cardiorenal axis.Heart Fail Rev. 2016 Mar;21(2):177-89. doi: 10.1007/s10741-016-9534-y. Heart Fail Rev. 2016. PMID: 26852141 Review.
-
The Role of Endotoxin in the Setting of Cardiorenal Syndrome Type 5.Cardiorenal Med. 2017 Oct;7(4):276-283. doi: 10.1159/000475846. Epub 2017 Jun 24. Cardiorenal Med. 2017. PMID: 29118766 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical